Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MyFastRx vs Vea Health

MyFastRx
Graded #172

Higher grade

vs+12.400000000000006
Vea Health
Graded #451

Lower grade

The verdict

MyFastRx takes it — 67.4/100 to 55/100.

MyFastRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyFastRx is a cash-pay compounded-GLP-1 platform built around fast approval and discounted multi-month bundles.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyFastRx +30
75
45
Dose & formulationMyFastRx +21
72
51
Clinical oversightEven
66
66
Labs & monitoringEven
52
52
FulfillmentMyFastRx +15
83
68
Contract termsVea Health +14
41
55
MyFastRx · left barVea Health · right bar

The numbers

MetricMyFastRxVea Health
WeighScore67.4/10055/100
GradeCC
Scorecard rank#172#451
Semaglutide$169/moNot disclosed
Tirzepatide$249/moNot disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
MyFastRx

Graded #172 · C

Strengths

  • Aggressive 12-month bundle pricing — $99/mo semaglutide, $149/mo tirzepatide
  • LegitScript certified
  • All doses priced the same — no cost escalation as you titrate up
  • First-month promo discount lowers the trial barrier

Where it loses points

  • States served not disclosed — only 'multiple states' / 'licensed U.S. providers'
  • Corporate address and medical director not published
  • Pharmacy partner not named — only 'state-licensed pharmacies'
  • Cash-pay only — no insurance billing
  • Bundle savings require a large upfront commitment (12 months billed at once)
Vea Health

Graded #451 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard